Cardiovascular and Renal Outcomes with Empagliflozin in …
2020年8月28日 · In patients with type 2 diabetes, sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and the risk of serious adverse renal events, benefits...
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
2021年8月27日 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been shown to reduce the development and progression of heart failure in patients with type 2 diabetes and...
Dapagliflozin in Patients with Chronic Kidney Disease | NEJM
2020年9月24日 · We designed the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial to assess the long-term efficacy and safety of the SGLT2 inhibitor dapagliflozin in...
SGLT2 Inhibitors Squeak Out a Win in Patients Post-MI - NEJM …
2024年1月23日 · James et al 1 report the results of the DAPA-MI (DAPAagliflozin in patients without diabetes mellitus with acute Myocardial Infarction) trial, which studied the efficacy and safety of early...
Should We Be Concerned About SGLT-2 Inhibitors Worsening …
2025年1月30日 · Some studies have suggested that sodium–glucose cotransporter-2 (SGLT-2) inhibitors are associated with modest excess risk for adverse peripheral arterial disease (PAD) events (NEJM JW Gen Med Sep 15 2018 and JAMA Intern Med 2018; 178:1190; NEJM JW Gen Med Aug 1 2017 and N Engl J Med 2017; 377:644). To examine this concern further ...
SGLT-2 Inhibitors for Heart Failure - NEJM Journal Watch
2022年9月6日 · Sodium–glucose cotransporter-2 (SGLT-2) inhibitors improve outcomes in patients with heart failure and reduced ejection fraction (HFrEF; EF, ≤40%), and NEJM Journal Watch reviews over 150 scientific and medical journals to present important clinical research findings and insightful commentary
Can SGLT2 Inhibitors ERASe Arrhythmias? | NEJM Evidence
2024年9月24日 · Initially developed for the treatment of type 2 diabetes mellitus, sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce hemoglobin A1c levels. 1 As part of regulatory requirements to...
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease | NEJM …
2023年5月19日 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of adverse cardiovascular and kidney outcomes in patients with type 2 diabetes (T2D), heart failure, and/or CKD....
NEJM前沿 | 得到验证，恩格列净可给慢性肾脏病患者带来长期心 …
6 天之前 · 恩格列净，一种钠-葡萄糖协同转运蛋-2（SGLT-2）抑制剂，在EMPA-KIDNEY试验中显示出对患有慢性肾脏病（CKD）且有疾病进展风险的受试者具有积极的心 ...
Should SGLT-2 Inhibitors Be Counted as Antihypertensive …
2024年11月19日 · Sodium–glucose cotransporter-2 (SGLT-2) inhibitors improve glycemic control in patients with type 2 diabetes and lower risk for adverse cardiovascular events, worsening heart failure, and chronic kidney disease progression.